Birchview Capital, LP — 13F Holdings & Portfolio

CIK 1618205 · latest 13F-HR filed 2026-05-15

Birchview Capital, LP manages $175.7M in 13F-reported U.S. long-equity assets across 73 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are KLAC (16.67%), BMY (10.57%), CMPX (4.41%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 17 new positions, exited 12, added to 20, and trimmed 26.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$175.7M

Long-equity book

Holdings

73

Distinct positions

Period

2026-03-31

Filed 2026-05-15

Q/Q Activity

+17 / −12 / ↑20 / ↓26

vs 2025-12-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • INTELLIA THERAPEUTICS INC$2.9M +101.4%
  • KLA CORPORATION$2.7M +10.1%
  • BRISTOL-MYERS SQUIBB CO$2.2M +13.7%
  • BIODESIX INC$2.2M +113.2%
  • OVINTIV INC$2.2M +51.5%
Show all 20

Top Trims

  • OLEMA PHARMACEUTICALS INC-$3.5M -51.4%
  • CASTLE BIOSCIENCES INC-$2.8M -89.9%
  • PHREESIA INC-$1.8M -93.6%
  • IMMUNOME INC-$1.7M -60.8%
  • STRUCTURE THERAPEUTICS INC-$1.4M -23.0%
Show all 26

New Positions

  • RELMADA THERAPEUTICS INC$2.8M
  • OCULAR THERAPEUTIX INC$2.7M
  • CELLDEX THERAPEUTICS INC$2.2M
  • COMPASS PATHWAYS LTD$2.1M
  • ENGENE HOLDINGS INC$1.7M
Show all 17

Exited Positions

  • AMICUS THERAPEUTICS INC$3.6M
  • MASIMO CORP$1.1M
  • 10X GENOMICS INC$962.3K
  • VENTYX BIOSCIENCES INC$910.5K
  • ILLUMINA INC$787.0K
Show all 12
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 KLA CORPORATION KLAC 482480100 $29.3M 16.67% 19,883 SH
2 BRISTOL-MYERS SQUIBB CO BMY 110122108 $18.6M 10.57% 306,268 SH
3 COMPASS THERAPEUTICS INC CMPX 20454B104 $7.8M 4.41% 1,465,867 SH
4 LAM RESEARCH CORPORATION LRCX 512807306 $7.7M 4.38% 36,000 SH
5 STOKE THERAPEUTICS INC STOK 86150R107 $6.8M 3.89% 210,000 SH
6 OVINTIV INC OVV 69047Q102 $6.4M 3.63% 107,500 SH
7 INTELLIA THERAPEUTICS INC NTLA 45826J105 $5.7M 3.25% 445,400 SH
8 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $4.8M 2.74% 100,000 SH
9 SOLID BIOSCIENCES INC SLDB 83422E204 $4.5M 2.57% 625,980 SH
10 PROTHENA CORP PLC PRTA G72800108 $4.4M 2.48% 449,019 SH
11 BIODESIX INC BDSX 09075X108 $4.2M 2.37% 286,804 SH
12 ACADIA PHARMACEUTICALS INC ACAD 004225108 $3.8M 2.17% 171,000 SH
13 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $3.7M 2.10% 35,000 SH
14 NEUROCRINE BIOSCIENCES INC NBIX 64125C109 $3.6M 2.04% 27,190 SH
15 OLEMA PHARMACEUTICALS INC OLMA 68062P106 $3.3M 1.86% 219,000 SH
16 RELMADA THERAPEUTICS INC RLMD 75955J402 $2.8M 1.62% 409,387 SH
17 OCULAR THERAPEUTIX INC OCUL 67576A100 $2.7M 1.54% 320,000 SH
18 UNITED THERAPEUTICS CORP UTHR 91307C102 $2.7M 1.52% 4,500 SH
19 NEKTAR THERAPEUTICS NKTR 640268306 $2.2M 1.27% 31,000 SH
20 CELLDEX THERAPEUTICS INC CLDX 15117B202 $2.2M 1.27% 70,095 SH
21 NOVOCURE LTD NVCR G6674U108 $2.2M 1.26% 202,330 SH
22 EQT CORPORATION EQT 26884L109 $2.2M 1.25% 34,619 SH
23 PHATHOM PHARMACEUTICALS INC PHAT 71722W107 $2.2M 1.23% 195,000 SH
24 BICYCLE THERAPEUTICS PLC BCYC 088786108 $2.2M 1.22% 463,599 SH
25 COMPASS PATHWAYS LTD CMPS 20451W101 $2.1M 1.18% 375,000 SH
26 PACIFIC BIOSCIENCES OF CALIFORNIA INC PACB 69404D108 $2.0M 1.13% 1,500,000 SH
27 CYTOKINETICS INC CYTK 23282W605 $2.0M 1.13% 30,000 SH
28 CORCEPT THERAPEUTICS INC CORT 218352102 $1.9M 1.08% 47,200 SH
29 VERA THERAPEUTICS INC VERA 92337R101 $1.8M 1.01% 44,000 SH
30 ALKERMES PLC ALKS G01767105 $1.8M 1.01% 50,000 SH
31 ENGENE HOLDINGS INC ENGNW 29286M105 $1.7M 0.97% 250,000 SH
32 UNIQURE NV QURE N90064101 $1.6M 0.94% 100,697 SH
33 ZENAS BIOPHARMA INC ZBIO 98937L105 $1.4M 0.78% 70,000 SH
34 QUIDELORTHO CORP 74838J101 $1.4M 0.77% 82,548 SH
35 FOGHORN THERAPEUTICS INC FHTX 344174107 $1.3M 0.77% 281,730 SH
36 ULTRAGENYX PHARMACEUTICAL INC RARE 90400D108 $1.3M 0.74% 62,000 SH
37 XENON PHARMACEUTICALS INC XENE 98420N105 $1.2M 0.70% 21,000 SH
38 KALVISTA PHARMACEUTICALS INC KALV 483497103 $1.1M 0.65% 57,000 SH
39 IMMUNOME INC IMNM 45257U108 $1.1M 0.62% 50,000 SH
40 FREEPORT-MCMORAN CL-B FCX 35671D857 $1.1M 0.60% 18,040 SH
41 AXSOME THERAPEUTICS INC AXSM 05464T104 $1.0M 0.58% 6,000 SH
42 BIOGEN INC BIIB 09062X103 $916.6K 0.52% 5,000 SH
43 LIPOCINE INC LPCN 53630X203 $893.2K 0.51% 111,786 SH
44 TRAVERE THERAPEUTICS INC TVTX 89422G107 $867.5K 0.49% 29,200 SH
45 HARROW HEALTH INC HROW 415858109 $846.2K 0.48% 24,000 SH
46 PHARVARIS N V PHVS N69605108 $843.2K 0.48% 29,847 SH
47 VERASTEM INC VSTM 92337C203 $795.0K 0.45% 150,000 SH
48 APOGEE THERAPEUTICS INC APGE 03770N101 $757.5K 0.43% 9,000 SH
49 HALOZYME THERAPEUTICS INC HALO 40637H109 $652.8K 0.37% 10,100 SH
50 BRIDGEBIO PHARMA INC BBIO 10806X102 $645.2K 0.37% 8,688 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-15 $175.7M 73 0001618205-26-000002
2025-12-31 2026-02-13 $170.8M 68 0001618205-26-000001
2025-09-30 2025-11-13 $132.4M 69 0001618205-25-000011